Download PDF
Semin Thromb Hemost 2018; 44(06): 561-567
DOI: 10.1055/s-0037-1612627
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective

Andrea Messori
1   HTA Unit, ESTAR, Regional Health Service, Firenze, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Abstract

A discussion of the main pharmacoeconomic issues related to inhibitors in hemophilia A cannot be separated from an analysis of the most relevant clinical questions. In the field of inhibitors, the clinical evidence includes several controversial topics, such as high-titer versus low-titer inhibitors, the influence of factor VIII products on inhibitor risk, effectiveness of different immune tolerance induction (ITI) treatments, the role of bypassing agents, and development of new non-factor-VIII compounds. In terms of pharmacoeconomic data, numerous cost estimates have been reported in these fields, but this information is strongly influenced by the wide between-country differences in unit costs. Quite reliable data are, however, available regarding expenditure for replacement therapy in patients without inhibitors, increased lifetime costs caused by high-titer inhibitors, and cost of pharmacological interventions aimed at eradicating inhibitors. As regards the cost-effectiveness ratio, the data on ITI are not conclusive; nonetheless, irrespective of the specific treatments employed for inducing tolerance, their costs seem to be offset by the subsequent savings in the cost per patient. Other issues, such as the cost of low-titer inhibitors in patients with hemophilia A and effectiveness of pharmacological interventions aimed at eradicating low-titer inhibitors are not supported by sound data and will require further research. Finally, although the efficacy and safety profiles of novel treatments (e.g., emicizumab, Roche) warrant long-term clinical studies, the economic advantages of these new compounds might be very substantial both in patients with inhibitors and in those at risk of developing inhibitors.

Keywords

hemophilia A - inhibitors - pharmacoeconomics - cost of illness
 

  • References

  • 1 Valente M, Cortesi PA, Lassandro G. , et al. Health economic models in hemophilia A and utility assumptions from a clinician's perspective. Pediatr Blood Cancer 2015; 62 (10) 1826-1831
    CrossrefPubMedGoogle Scholar
  • 2 Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 2015; 21 (03) 310-319
    CrossrefPubMedGoogle Scholar
  • 3 Farrugia A, Cassar J, Kimber MC. , et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19 (04) e228-e238
    CrossrefPubMedGoogle Scholar
  • 4 Rasekh HR, Imani A, Karimi M, Golestani M. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. Clinicoecon Outcomes Res 2011; 3: 207-212
    PubMedGoogle Scholar
  • 5 Escobar MA. Health economics in haemophilia: a review from the clinician's perspective. Haemophilia 2010; 16 (Suppl. 03) 29-34
    PubMedGoogle Scholar
  • 6 Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin 2008; 24 (03) 753-768
    CrossrefPubMedGoogle Scholar
  • 7 Drummond M, Houwing N, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia 2017; 23 (02) e58-e66
    CrossrefPubMedGoogle Scholar
  • 8 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014; 124 (23) 3365-3372
    CrossrefPubMedGoogle Scholar
  • 9 Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santagostino E, Makris M. New findings on inhibitor development: from registries to clinical studies. Haemophilia 2017; a; 23 (Suppl. 01) 4-13
    CrossrefPubMedGoogle Scholar
  • 10 Antunes SV, Tangada S, Stasyshyn O. , et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20 (01) 65-72
    CrossrefPubMedGoogle Scholar
  • 11 Qi X, Zhao Y, Li K, Fan L, Hua B. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Blood Coagul Fibrinolysis 2014; 25 (07) 754-760
    CrossrefPubMedGoogle Scholar
  • 12 Peyvandi F, Mannucci PM, Garagiola I. , et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med 2016; a; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 13 Franchini M, Coppola A, Rocino A. , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (07) 752-766
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gouw SC, van der Bom JG, Ljung R. , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (03) 231-239
    CrossrefPubMedGoogle Scholar
  • 15 Fischer K, Lassila R, Peyvandi F. , et al; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113 (05) 968-975
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Peyvandi F, Mannucci PM, Palla R, Rosendaal FR. SIPPET: methodology, analysis and generalizability. Haemophilia 2017; 23 (03) 353-361
    CrossrefPubMedGoogle Scholar
  • 17 Hay CR, Palmer BP, Chalmers EA. , et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 2015; 21 (02) 219-226
    CrossrefPubMedGoogle Scholar
  • 18 Coppola A, Marrone E, Conca P. , et al. Safety of switching factor VIII products in the era of evolving concentrates: myths and facts. Semin Thromb Hemost 2016; 42 (05) 563-576
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4 (12) 2576-2581
    CrossrefPubMedGoogle Scholar
  • 20 Holstein K, Batorova A, Carvalho M. , et al; European Haemophilia Therapy Strategy Board (EHTSB). Current view and outcome of ITI therapy-A change over time?. Thromb Res 2016; 148: 38-44
    CrossrefPubMedGoogle Scholar
  • 21 Hay CR, DiMichele DM. ; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (06) 1335-1344
    CrossrefPubMedGoogle Scholar
  • 22 Rocino A, Coppola A, Franchini M. , et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
    PubMedGoogle Scholar
  • 23 Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost 2016; 116 (Suppl. 01) S10-S17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Astermark J, Donfield SM, DiMichele DM. , et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (02) 546-551
    CrossrefPubMedGoogle Scholar
  • 25 Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM. High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfus 2017; b; 15: 1-7
    PubMedGoogle Scholar
  • 26 Abrahamyan L, Willan AR, Beyene J, Mclimont M, Blanchette V, Feldman BM. ; Canadian Hemophilia Primary Prophylaxis (CHPS) Study Group. Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A. J Gen Intern Med 2014; 29 (Suppl. 03) S767-S773
    CrossrefPubMedGoogle Scholar
  • 27 Elder-Lissai A, Hou Q, Krishnan S. The changing costs of caring for hemophilia patients in the u.s.: insurers' and patients' perspectives. Presented at: the Annual Meeting of the American Society of Hematology; December 6–9, 2014; San Francisco, CA. Abstract # 199
    PubMedGoogle Scholar
  • 28 Gringeri A, Mantovani LG, Scalone L, Mannucci PM. ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (07) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 29 Maratea D, Fadda V, Trippoli S, Messori A. Economic analysis of not undertaking tenders for recombinant factor VIII procurement: a simplified analysis to estimate an otherwise unknown pharmacoeconomic index. Eur J Hosp Pharm 2016; 23: 219-223
    CrossrefPubMedGoogle Scholar
  • 30 Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96 (05) 1698-1702
    CrossrefPubMedGoogle Scholar
  • 31 Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008; 99 (06) 1060-1067
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia 2014; 20 (Suppl. 06) 17-26
    CrossrefPubMedGoogle Scholar
  • 33 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6 (04) E46
    CrossrefPubMedGoogle Scholar
  • 34 Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A. ; European Haemophilia Therapy Strategy Board (EHTSB); European Haemophilia Therapy Strategy Board EHTSB. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016; 22 (01) 96-102
    CrossrefPubMedGoogle Scholar
  • 35 Aznar JA, Moret A, Ibáñez F. , et al. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. Haemophilia 2014; 20 (05) 624-629
    CrossrefPubMedGoogle Scholar
  • 36 Sharathkumar A, Lillicrap D, Blanchette VS. , et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1 (06) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 37 Fischer K, Iorio A, Lassila R. , et al; EUHASS Participants. Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost 2015; 114 (04) 670-675
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Messori A, Peyvandi F, Mengato D, Mannucci PM. Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies. Haemophilia 2017; a; 23 (02) e87-e92
    CrossrefPubMedGoogle Scholar
  • 39 van den Berg HM, Hashemi SM, Fischer K. , et al; PedNet Study group. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thromb Haemost 2016; 115 (04) 729-737
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 657-662
    CrossrefPubMedGoogle Scholar
  • 41 Castaman G, Fijnvandraat K. Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. Blood 2014; 124 (15) 2333-2336
    CrossrefPubMedGoogle Scholar
  • 42 Nance D, Fletcher SN, Bolgiano DC, Thompson AR, Josephson NC, Konkle BA. Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild haemophilia A. Haemophilia 2013; 19 (05) 720-726
    CrossrefPubMedGoogle Scholar
  • 43 Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K. Emerging issues in diagnosis, biology, and inhibitor risk in mild hemophilia A. Semin Thromb Hemost 2016; 42 (05) 507-512
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?. Haemophilia 2013; 19 (02) 174-180
    CrossrefPubMedGoogle Scholar
  • 45 Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007; 25 (12) 1007-1029
    CrossrefPubMedGoogle Scholar
  • 46 Astermark J, Rocino A, Von Depka M. , et al; EHTSB. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13 (01) 38-45
    PubMedGoogle Scholar
  • 47 Jimenez-Yuste V, Núñez R, Romero JA, Montoro B, Espinós B. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia 2013; 19 (06) 841-846
    CrossrefPubMedGoogle Scholar
  • 48 Salaj P, Penka M, Smejkal P. , et al. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Thromb Res 2012; 129 (05) e233-e237
    CrossrefPubMedGoogle Scholar
  • 49 Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Haemophilia 2015; 21 (03) 320-329
    CrossrefPubMedGoogle Scholar
  • 50 Coppola A, Windyga J, Tufano A, Yeung C, Di Minno MN. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev 2015; (02) CD009961
    PubMedGoogle Scholar
  • 51 Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80 (05) 773-778
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. ; NovoSeven in Surgery Study Investigators. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98 (04) 726-732
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Pokras SM, Petrilla AA, Weatherall J, Lee WC. The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis. Haemophilia 2012; 18 (02) 284-290
    CrossrefPubMedGoogle Scholar
  • 54 Shima M, Hanabusa H, Taki M. , et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053
    CrossrefPubMedGoogle Scholar
  • 55 Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19 (05) 660-667
    CrossrefPubMedGoogle Scholar